Laurus Labs
![]() | |
Type | Public company |
---|---|
NSE: LAURUSLABS BSE: 540222 | |
Industry | Pharmaceuticals |
Founded | 2005[1] |
Founders | Dr.Satyanarayana Chava |
Headquarters | , India |
Number of locations | 6 |
Area served | Global |
Key people | |
Services | Generics API, Generics FDF, Synthesis & Biotechnology |
Revenue | 375+ USD in MN - FY20, 280+ USD in MN - H1 FY21 |
Number of employees | 4000 plus |
Divisions | API, FDF, Synthesis, Biotech |
Subsidiaries | Laurus Synthesis, Laurus Bio, Laurus Ingredients, Sriam |
Website | lauruslabs |
Laurus Labs is an Indian pharma and biotech company headquartered in Hyderabad, with its manufacturing plants located at Visakhapatnam, Hyderabad and Bengaluru. Its focus areas include active pharma ingredients, finished dosage forms, synthesis and biotechnology.[4]
![Scientist at Laurus Labs R&D.jpg](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a3/Scientist_at_Laurus_Labs_R%26D.jpg/264px-Scientist_at_Laurus_Labs_R%26D.jpg)
Laurus Labs manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA.[5] The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.[citation needed]
Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest [6]HiPotent API capacities in India[7] The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS,[8][9] and hydroxychloroquine tablets, which are used to treat certain types of malaria.[10]
In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.[11]
The company has eight manufacturing facilities located in Visakhapatnam Hyderabad and Bengaluru. The R&D centres are based in Hyderabad, Visakhapatnam and United States.
References[12][13][]
- ^ "Laurus Labs Ltd". Bloomberg. Retrieved 17 April 2020.
- ^ "Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts". Moneycontrol. Retrieved 17 April 2020.
- ^ "Laurus Labs: A hot startup in the pharma sector". Forbes India. Retrieved 17 April 2020.
- ^ "Laurus Labs Share Price: Company forays into Lucrative Biotech Space". Zee Business. 2020-11-27. Retrieved 2020-11-27.
- ^ Trivedi, Isha. "Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead". The Economic Times. Retrieved 2020-10-19.
- ^ Laurus Labs. "Investor Presentation" (PDF).
- ^ "Laurus Labs eyes bigger play in generic formulations segment". Times of India. Retrieved 17 April 2020.
- ^ "Laurus Labs gets USFDA nod for HIV drug". Economic Times Health. Retrieved 17 April 2020.
- ^ "Laurus Labs is ready to flood the US with cheap HIV drugs". Livemint. Retrieved 17 April 2020.
- ^ "Laurus Labs gets USFDA nod for malaria tablets". The Hindu Business Line. Retrieved 17 April 2020.
- ^ "Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US". Moneycontrol. Retrieved 17 April 2020.
- ^ Money Control (May 3, 2021). "Laurus Labs: Diversification to speed up in FY23; add on declines". Money Control. Retrieved May 3, 2021.
- ^ Money Control (May 4). "Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth plan". Money Control. Retrieved May 4, 2021. Check date values in:
|date=
(help)
- ^ "Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%". www.indiainfoline.com. Retrieved 2021-01-20.
- Pharmaceutical companies of India
- Pharmaceutical companies established in 2005
- Manufacturing companies based in Hyderabad, India
- 2005 establishments in Andhra Pradesh
- Companies listed on the National Stock Exchange of India
- Companies listed on the Bombay Stock Exchange